AAV CNS Gene Delivery Using BBB-Crossing Peptide Mediation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The efficiency of viral vector-mediated neuronal transduction in the central nervous system (CNS) is low, primarily transducing astrocytes and endothelial cells, necessitating improved methods for high-efficiency gene transfer.
Innovation Solution
Administering a viral vector with a hydrophilic peptide conjugated to a blood-brain barrier (BBB) receptor ligand, such as K16ApoE, to enhance nucleic acid delivery across the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of AAV are administered to achieve sufficient gene delivery to the CNS, then transduction efficiency improves, but toxicity and immune responses worsen
Solution Approach 1:
The patent uses a transcytosis-mediated delivery system where the AAV vector is transported across the BBB via an intermediary mechanism involving receptor-mediated endocytosis and transcytosis, rather than direct administration. This intermediary transport pathway allows the vector to cross the BBB efficiently without requiring high doses, thereby reducing toxicity and immune responses while maintaining gene delivery efficiency.
2Ease of manufacture
If traditional AAV administration methods are used, then the delivery process is simple, but transduction of CNS cells remains inefficient
Solution Approach 1:
The patent modifies key parameters of the AAV vector including capsid protein composition (e.g., AAV2/9 hybrid capsids), pseudotyping, and surface modifications to enhance transcytosis capability. These parameter changes enable the vector to efficiently cross the BBB and transduce CNS cells while maintaining a relatively simple intravenous administration protocol, thus improving transduction efficiency without significantly complicating the administration process.
3Device complexity
If the blood-brain barrier is not considered in delivery design, then the delivery system is simpler, but CNS gene delivery efficiency deteriorates
Solution Approach 1:
The patent employs preliminary design of the AAV vector with specific capsid modifications and pseudotyping that are pre-optimized for BBB transcytosis. This preliminary action of engineering the vector with inherent transcytosis capabilities eliminates the need for complex delivery systems or BBB disruption procedures, achieving efficient CNS gene delivery through a relatively simple modified vector design combined with standard intravenous administration.
Data Source
Figure 1A~1J
Figure 1E~1L
Figure 2
AI summary
The disclosure relates, in some aspects, to compositions and methods for enhanced delivery of a transgene to the central nervous system (CNS) of a subject. In some embodiments, the transgene is delivered by recombinant AAV (rAAV). In some embodiments, the method of enhancing transgene delivery comprises administering a blood brain barrier (BBB)-crossing molecule (e.g., K16ApoE) and an rAAV comprising a transgene to a subject.